Zonisamide decreases ethanol intake in rats and mice

Pharmacology Biochemistry and Behavior

Volumn 87, Issue 1, 2007, Pages 65-72

  Knapp, Clifford M ^a   Mercado, Melissa ^a   Markley, Tara Lynn ^a   Crosby, Steven ^a   Ciraulo, Domenic A ^a   Kornetsky, Conan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol; Alcoholism; Novel anticonvulsants; Sulfamates; Sulfonamides; Topiramate; Zonisamide

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; LACTOSE; SUCROSE; TOPIRAMATE; ZONISAMIDE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG DOSE INCREASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; TREATMENT OUTCOME;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUCTOSE; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; SUCROSE;

MUS; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 34249805094     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.04.001     Document Type: Article

References (71)

1. Angehagen M., Ben-Menachem E., Shank R., Ronnback L., and Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem 88 (2004) 320-325
2. Astrup A., Caterson I., Zelissen P., Guy-Grand B., Carruba M., Levy B., et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 12 (2004) 1658-1669
3. Bisaga A., and Evans S.M. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend 83 (2006) 25-32
4. Borowicz K.K., Luszczki J.J., Sobieszek G., Ratnaraj N., Patsalos P.N., and Czuczwar S.A. Interactions between zonisamide and conventional antiepileptic drugs in the mouse maximal electroshock test model. Eur Neuropsychopharmacol 17 (2007) 265-272
5. Brady K.T., Myrick H., Henderson S., and Coffey S.F. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend 67 (2002) 323-330
6. Brown R.O., Orr C.D., Hanna D.L., Williams J.E., and Dickerson R.N. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy 22 (2002) 831-835
7. Carpenter L.L., Leon Z., Yasmin S., and Price L.H. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord 69 (2002) 251-255
8. Chengappa K.N., Chalasani L., Brar J.S., Parepally H., Houck P., and Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 24 (2002) 1576-1584
9. Ciraulo D.A., Knapp C.M., Crosby S., and Kornetsky C. The Effects of topiramate and zonisamide in combination with alcohol on spatial memory. Neurospsychopharmacol 31 1 (2006) S79-S90
10. Croissant B., Scherle T., Diehl A., Heinz A., and Mann K. Oxcarbazepine in alcohol relapse prevention-a case series. Pharmacopsychiatry 37 (2004) 306-307
11. Finn D.A., Sinnott R.S., Ford M.M., Long S.L., Tanchuck M.A., and Phillips T.J. Sex differences in the effect of ethanol injection and consumption on brain allopregnanolone levels in C57BL/6 mice. Neuroscience 123 (2004) 813-819
12. Gabriel K.I., and Cunningham C.L. Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res 29 (2005) 75-80
13. Gadde K.M., Franciscy D.M., Wagner II H.R., and Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289 (2003) 1820-1825
14. Gardell L.R., Whalen C.A., Chambers M.D., Boswell K.J., Hubbell C.L., and Reid L.D. Valproate reduces intake of alcoholic beverage among rats. Behav Pharmacol 9 (1998) 683-689
15. Gibbs III J.W., Sombati S., DeLorenzo R.J., and Coulter D.A. Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 1 (2000) S10-S16
16. Gilpin N.W., Stewart R.B., Murphy J.M., Li T.K., and Badia-Elder N.E. Neuropeptide Y reduces oral ethanol intake in alcohol-preferring (P) rats following a period of imposed ethanol abstinence. Alcohol Clin Exp Res 27 (2003) 787-794
17. Gilpin N.W., Stewart R.B., Murphy J.M., and Badia-Elder N.E. Neuropeptide Y in the paraventricular nucleus of the hypothalamus increases ethanol intake in high- and low-alcohol-drinking rats. Alcohol Clin Exp Res 28 (2004) 1492-1498
18. Gilpin N.W., Stewart R.B., Murphy J.M., and Badia-Elder N.E. Sensitized effects of neuropeptide Y on multiple ingestive behaviors in P rats following ethanol abstinence. Pharmacol Biochem Behav 81 (2005) 740-749
19. Gremel C.M., Gabriel K.I., and Cunningham C.L. Topiramate does not affect the acquisition or expression of ethanol conditioned place preference in DBA/2J or C57BL/6J mice. Alcohol Clin Exp Res 30 (2006) 783-790
20. Gryder D.S., and Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23 (2003) 7069-7074
21. Hamada K., Song H.K., Ishida S., Yagi K., and Seino M. Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling in rats. Epilepsia 42 (2001) 1379-1386
22. Hayes D.M., Knapp D.J., Breese G.R., and Thiele T.E. Comparison of basal neuropeptide Y and corticotropin releasing factor levels between the high ethanol drinking C57BL/6J and low ethanol drinking DBA/2J inbred mouse strains. Alcohol Clin Exp Res 29 (2005) 721-729
23. Huang C.W., Ueno S., Okada M., and Kaneko S. Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res 67 (2005) 51-60
24. Husum H., Van Kammen D., Termeer E., Bolwig G., and Mathe A. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 28 (2003) 1292-1299
25. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361 (2003) 1677-1685
26. Kim S.G., Han B.D., Park J.M., Kim M.J., and Stromberg M.F. Effect of the combination of naltrexone and acamprosate on alcohol intake in mice. Psychiatry Clin Neurosci 58 (2004) 30-36 Feb
27. Kitano Y., Komiyama C., Makino M., Takasuna K., Takazawa A., and Sakurada S. Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats. Epilepsia 46 (2005) 811-818
28. Kito M., Maehara M., and Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5 (1996) 115-119
29. Kranzler H.R., Bauer L.O., and Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend 38 3 (1995) 203-211
30. Le A.D., Ko J., Chow S., and Quan B. Alcohol consumption by C57BL/6, BALB/c, and DBA/2 mice in a limited access paradigm. Pharmacol Biochem Behav 47 (1994) 375-378
31. Leite-Morris K., and Ciraulo D.A. Novel anticonvulsant zonisamide reduces ethanol seeking and consumption in rats. Abstract. Research Society on Alcoholism (2007)
32. Longo L.P., Campbell T., and Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 2 (2002) 55-64
33. Maryanoff B.E., Costanzo M.J., Nortey S.O., Greco M.N., Shank R.P., Schupsky J.J., et al. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 41 (1998) 1315-1343
34. Maryanoff B.E., McComsey D.F., Costanzo M.J., Hochman C., Smith-Swintosky V., and Shank R.P. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem 48 (2005) 1941-1947
35. Masuda Y., and Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 43 (1993) 416-418
36. Masuda Y., Utsui Y., Shiraishi Y., Karasawa T., Yoshida K., and Shimizu M. Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 20 (1979) 623-633 Dec
37. Masuda Y., Karasawa T., Shiraishi Y., Hori M., Yoshida K., and Shimizu M. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforschung 30 (1980) 477-483
38. McElroy S.L., Kotwal R., Hudson J.I., Nelson E.B., and Keck P.E. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 65 (2004) 50-56
39. Messiha F.S., Butler D., and Adams M.K. Carbamazepine and ethanol elicited responses in rodents. Alcohol 3 (1986) 131-133
40. Minuk G.Y., Rockman G.E., German G.B., Duerksen D.R., Borrett G., and Hoeschen L. The use of sodium valproate in the treatment of alcoholism. J Addict Dis 14 (1995) 67-74
41. Mueller T.I., Stout R.L., Rudden S., Brown R.A., Gordon A., Solomon D.A., et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 21 (1997) 86-92
42. Nagatomo I., Yasuaki A., Nagase F., Nomaguchi M., and Takigawa M. Relationships between convulsive seizures and serum brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. Brain Res 731 (1996) 190-198
43. Nakamura J., Tamura S., Kanda T., Ishii A., Ishihara K., Serikawa T., et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 254 (1994) 83-89 Mar 11
44. Nguyen S.A., DeLeon C.P., Malcolm R.J., and Middaugh L.D. Tiagabine reduces ethanol reward in C57BL/6 mice under acute and chronic administration regimens. Synapse 56 (2005) 135-146
45. Nguyen S.A., Malcolm R., and Middaugh L.D. Topiramate reduces ethanol consumption in C57BL/6 mice. Synapse 61 (2007) 150-156
46. Nurmi M., Kiianmaa K., and Sinclair J.D. Brain ethanol levels after voluntary ethanol drinking in AA and Wistar rats. Alcohol 19 (1999) 113-118
47. O'Callaghan M.J., Croft A.P., Watson W.P., Brooks S.P., and Little H.J. Low alcohol preference among the "high alcohol preference" C57/BL10 mice; factors affecting such preference. Pharmacol Biochem Behav 72 (2002) 475-481
48. Qian J., and Noebels J.L. Topiramate alters excitatory synaptic transmission in mouse hippocampus. Epilepsy Res 55 (2003) 225-233
49. Rimondini R., Sommer W., and Heilig M. Effects of tiagabine and diazepam on operant ethanol self-administration in the rat. J Stud Alcohol 63 (2002) 100-106
50. Rock D.M., Macdonald R.L., and Taylor C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 3 (1989) 138-143
51. Rubio G., Ponce G., Jimenez-Arriero M.A., Palomo T., Manzanares J., and Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37 (2004) 37-40
52. Rubio G., Lopez-Munoz F., and Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 8 (2006) 289-293
53. Salloum I.M., Cornelius J.R., Daley D.C., Kirisci L., and Himmelhoch J.M. Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 62 (2005) 37-45
54. Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 413 (1987) 185-188 Jun9
55. Schmitt U., Waldhofer S., Weigelt T., and Hiemke C. Free-choice ethanol consumption under the influence of GABAergic drugs in rats. Alcohol Clin Exp Res 26 (2002) 457-462
56. Schroeder J.P., Overstreet D.H., and Hodge C.W. The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol 36 (2005) 179-186
57. Shank R.P., Gardocki J.F., Streeter A.J., and Marynoff. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanisms of action. Epilepsia 41 Suppl 1 (2000) S3-S9
58. Shannon H.E., Eberle E.L., and Peters S.C. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology 48 (2005) 1012-1020
59. Skradski S., and White H.S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41 1 (2000) S45-S47
60. Sparta D.R., Fee J.R., Hayes D.M., Knapp D.J., MacNeil D.J., and Thiele T.E. Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. Alcohol Clin Exp Res 28 (2004) 1324-1330
61. Stromberg M.F., Casale M., Volpicelli L., Volpicelli J.R., and O'Brien C.P. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15 (1998) 281-289 May
62. Stromberg M.F., Rukstalis M.R., Mackler S.A., Volpicelli J.R., and O'Brien C.P. A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav 72 (2002) 483-490 May
63. Suzuki S., Kawakami K., Nakamura F., Nishimura S., Yagi K., and Seino M. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12 (1992) 21-27
64. + current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Th 288 (1999) 960-968
65. Tonstad S., Tykarski A., Weissgarten J., Ivleva A., Levy B., Kumar A., et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 96 (2005) 243-251
66. Tutka P., Mroz T., Klucha K., Piekarczyk M., and Wielosz M. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 64 (2005) 13-22
67. Uno H., Kurokawa M., Masuda Y., and Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 22 (1979) 180-183 Feb
68. Wilding J., Van Gaal L., Rissanen A., Vercruysse F., and Fitchet M. OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28 (2004) 1399-1410
69. York D.A., Singer L., Thomas S., and Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16 (2000) 967-975
70. Zhang X., Velumian A.A., Jones O.T., and Carlen P.L. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41 1 (2000) S52-S60
71. Zona C., Ciotti M.T., and Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 231 (1997) 123-126